North America's oldest pterosaur, a winged reptile, discovered in Arizona
Pterosaurs were the first vertebrates to develop powered flight, soaring above dinosaurs and other surreal creatures that called the prehistoric world home. The finding, detailed in an article in PNAS published Monday, offers clues to the evolution of the winged reptiles, which have more than 150 named species, including the Hollywood favorite — the pterodactyl.
Before the study, there were only two known Triassic pterosaurs from North America, Ben Kligman, a paleontologist at the Smithsonian's National Museum of Natural History and an author on the study, said in an email. This the only early pterosaur globally whose precise age has been determined — 209.2 million years old — information that is crucial to understanding 'how a fossil animal fits into patterns of evolutionary and environmental change,' he said.
Suzanne McIntire, formerly a volunteer with the museum, unearthed the fossil. 'What was exciting about uncovering this specimen was that the teeth were still in the bone, so I knew the animal would be much easier to identify,' she said in a statement.
The pterosaur's jaw holds worn-down teeth, suggesting it ate fish with armored scales, and the creature 'would have been small enough to comfortably perch on a person's shoulder,' according to the release.
Call the new species the 'ash-winged dawn goddess,' as the team has named it, or a small nightmare, as anyone imagining a winged reptile on their shoulder might. Regardless, it's a noteworthy discovery from the Petrified Forest National Park site, from which teams at the museum have uncovered more than 1,200 individual fossils, including fish scales, teeth and fossilized poop.
The fossils offer a window into a vibrant, bygone ecosystem, where animals such as giant amphibians, some up to six feet long, and armored crocodile relatives lived among 'evolutionary upstarts' such as frogs, turtles and pterosaurs. 'Fossil beds like these enable us to establish that all of these animals actually lived together,' Kligman said.
Among the findings was an ancient turtle 'with spike-like armor and a shell that could fit inside a shoebox,' the news release says. It's believed to have lived around the same time as the oldest known turtle, suggesting the creatures spread across the supercontinent Pangaea quickly. 'Surprising for an animal that is not very large and is likely walking at a slow pace,' Kligman noted.
Contrary to common belief, pterosaurs are not dinosaurs — their name comes from 'winged lizard' in Greek. Some were the size of paper airplanes while others were as big as fighter jets and feasted on baby dinosaurs. They went extinct around 66 million years ago.
The early evolution of pterosaurs is something of a mystery as they appeared in the fossil record some 215 million years ago with fully evolved wings, Kligman noted. Bones of pterosaurs from the Triassic era, about 251.9 to 201.3 million years ago, are also small, thin and often hollow, so they are easily destroyed before fossilization.
Scientists have named the newly discovered pterosaur Eotephradactylus mcintireae. The genus name, Eotephradactylus, refers to Eos, the goddess of dawn; tephra translates to ash, and dactyl refers to the fingerlike wings — referencing volcanic ash at the site of its discovery and the animals' position near the base of the pterosaur's evolutionary tree. The species name is a callback to its discoverer, McIntire.
The unearthed fossil is 'one of the only early pterosaurs whose anatomy can be observed in a detailed way in three dimensions,' Kligman said.
Its teeth are especially noteworthy as they're fused into the socket, a feature shared with small, slender Triassic reptiles known as lagerpetids, a group which some hypothesize may be closely related to pterosaurs.
Kligman called the setting of the finding, which he described as 'a river system flowing through the arid sub-tropical floodplains of central Pangaea,' unusual for early pterosaurs, and said there may be similar river deposits from other Triassic rocks that can also preserve pterosaur bones.
He said they hope 'this creates a new search-image for filling gaps in the early evolution of pterosaurs.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gizmodo
an hour ago
- Gizmodo
The Movie Everyone Thought Would Be ‘Dune Messiah' Is Now Officially ‘Dune: Part 3'
Though there's still no official release date, Dune fans have long assumed director Denis Villeneuve is readying production on the third film in the sci-fi series. Some casting news a few weeks back helped strengthen that notion—and now we have a title locked in. Surprisingly, it's not Dune Messiah, in keeping with Frank Herbert's source-material novel. It's… drum roll… Dune: Part Three. According to Variety, Dune: Part Three is still expected to release in December 2026, the slot previously reserved for an 'event movie' from the director by Warner Bros. At the time, the given date of December 18, 2026, conflicted with an unnamed Star Wars project that has since been removed—but is now the release date for a little movie called Avengers: Doomsday. So it's anyone's guess if Dune: Part Three will remain in place. (Lest we forget, Dune: Part Two shifted release dates a few times and was still a massive hit.) The Variety piece also notes that while some sequences in Dune: Part Three will be filmed using IMAX cameras, the whole film will not be shot in the format, as had been suggested by IMAX CEO Paul Gelfond. That means Christopher Nolan's currently in production The Odyssey will remain the only film entirely shot using IMAX cameras, at least until the next ambitious filmmaker takes the plunge. (Perhaps it'll still be Villeneuve, once he shifts gears to start work on his James Bond movie?) The trade notes that Dune: Part Three is expected to begin filming 'imminently,' with Timothée Chalamet and Zendaya returning to star. Jason Momoa, absent from Part Two, is also back in the cast. Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what's next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.


Gizmodo
2 hours ago
- Gizmodo
The Next Big Cancer Treatment Could Be Herpes
Scientists are developing all sorts of potential new treatments to tackle the most difficult cancer cases—including some that will make you thankful for the existence of herpes and other viruses. Clinical trial data out today shows that a modified version of the herpes simplex virus 1 (HSV-1) can help keep late-stage skin cancer at bay. Researchers at the University of Southern California and others conducted the study, a Phase I/II trial of people with advanced, treatment-resistant melanoma. About a third of patients given the modified virus, in combination with immunotherapy, saw their tumors substantially shrink, while some even experienced a complete regression of their cancer. A larger, definitive trial of the experimental therapy, code-named RP1, is already underway, and the Food and Drug Administration will decide on an approval later this month. Scientists have been intrigued about the promise of cancer-fighting, or oncolytic, viruses for over a century, according to study author Gino In, a medical oncologist at USC's Keck School of Medicine. But it's only recently that this potential has started to look within reach. 'Most progress has been made just in the last few decades, thanks to advances and progression in gene editing technologies, which have allowed researchers to specifically design oncolytic viruses that are more effective and safer,' In told Gizmodo. HSV-1, the primary cause of cold sores, has emerged as a particularly promising candidate for cancer treatment. HSV-1 is a relatively large virus, meaning scientists can replace or add new genes without too much trouble. And though it does use our cells to replicate, like any virus, it doesn't insert its DNA into a cell's genome directly, eliminating the risk of certain mutations (an important consideration for safety). A typical HSV-1 infection also isn't life-threatening and can be treated with antiviral medications if needed, further limiting its potential danger. These properties have allowed scientists to create strains of the virus that can selectively target cancer cells. The first herpes-based cancer therapy (T-VEC) was approved in the U.S. in 2015 for some cases of metastatic melanoma. But researchers like In are especially excited by the new generation of these treatments. A Cancer-Fighting Version of Herpes Shows Promise in Early Human Trial RP1 is the brainchild of biotech company Replimune, and it's one of several cancer-fighting viruses that the company is currently developing. Compared to the typical HSV-1 virus, RP1 has been weakened, meaning it shouldn't be able to cause severe infections. It's also been modified to not only target cancer cells, but to also boost the immune system's natural tumor-killing ability. 'These changes make RP1 both safer and better at killing cancer cells than natural HSV-1,' In explained. And while RP1 might be a viable treatment on its own, Replimune is also testing whether it can be even more effective when paired with other existing immunotherapies. This latest study involved 140 patients from the company's IGNYTE trial of RP1 conducted across several sites, including at USC. The participants had late-stage melanoma that was unresponsive to earlier immunotherapy treatment. They received both RP1 and nivolumab, an immunotherapy drug commonly used for melanoma, every two weeks for up to four months. If patients responded to the initial treatment, they continued taking nivolumab alone for up to two years. By the study's end, a third of patients saw their tumors decrease in size by at least 30%, the researchers found, and almost one in every six patients had their tumors disappear entirely. Importantly, this shrinkage was seen in tumors directly injected with RP1 as well as uninjected tumors throughout the body—indicating its immune-boosting potential worked as hoped. The combination therapy also appeared to be safe, with most patients only experiencing minor adverse events like fatigue or other flu-like symptoms. The findings were presented earlier this year at the annual meeting of the American Society of Clinical Oncology and are set to be published soon in the Journal of Clinical Oncology. 'This study provides an important new approach for patients with immunotherapy-refractory melanoma; this is very important since about half of all melanoma patients do not benefit from immunotherapy,' said In. 'So it provides a new type of treatment, one that is both effective and well tolerated.' Experimental Therapy Fights Brain Cancer with Modified Herpes Virus Early trials are primarily intended to vet an experimental treatment's safety and optimal dosing, not its effectiveness. But given the general outlook of these normally untreatable cases, there's certainly reason to be optimistic here. Last year, Replimune launched a Phase III trial that will test RP1 combined with nivolumab in around 400 people with treatment-resistant melanoma. But even before this study concludes, RP1 could become available to the public. In January, the FDA agreed to consider the combination therapy for accelerated approval, a process that allows a novel treatment to be tentatively approved with less direct evidence of its effectiveness (further trial data is still required to secure a full approval). The FDA's decision on RP1 is scheduled for July 22. In and the USC team will continue to study their data to better understand how RP1 works. But they expect RP1 to become a new option for these resistant melanoma cases, and In notes that RP1 is also being tested for other kinds of cancer. If things keep going right, virus-based therapies like RP1 could soon become the next frontier of cancer treatment.


Washington Post
2 hours ago
- Washington Post
Oprah's book club pick ‘Culpability' taps into our AI anxiety
Artificial intelligence is accelerating faster than a Tesla toward an oak tree. Every day brings a fresh story — possibly written by AI — about the wonders of a world remastered by autonomous billionaires and their silicon golems. Perplexity, indeed. Bruce Holsinger's novel 'Culpability,' about a deadly crash involving a self-driving vehicle, was originally slated for October, but Oprah just named it her July book club pick, so you can already find it parked in your local bookstore. Whatever the reason, that was a fortuitous rescheduling. When it comes to writing about artificial intelligence, three months is the distance between rubbing sticks together and splitting an atom.